On-Demand Webcast: Polycythemia Vera and Myelofibrosis: Expert Perspectives
  • CME

In this on-demand Webcast of a live symposium in Atlanta, Georgia, expert faculty review optimal care for patients with PV or MF, including differential diagnoses and current and emerging treatment approaches.
Srdan Verstovsek, MD, PhD
Program Director
person default
John Mascarenhas, MD
person default
Raajit K. Rampal, MD, PhD
Brady L. Stein, MD, MHS
Physicians: maximum of 2.5 AMA PRA Category 1 Credits
Released: January 31, 2018 Expiration: January 30, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Utilize clinical evidence and updated multiparameter criteria to help to distinguish PV and MF from reactive conditions and discriminating among them the Philadelphia chromosome–negative MPNs
  • Discuss the impact of mutational profiling in the management of PV and MF
  • Tailor therapy for patients with high-risk or aggressive PV using evidence-based guidance on best practices, safety considerations, available research data
  • Develop a plan to select second-line therapies for patients with PV who are refractory/relapsed to first-line agents
  • Critically interpret most recent results of clinical trials to optimize treatment/management of MF in the era of JAK inhibition
  • Evaluate the clinical data on promising agents and combination regimens likely to improve outcomes for patients with PV and MF
  • Identify ongoing trials for the treatment of PV to aid referral of patients for study participation

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Blueprint Medicines, Bristol‐Myers Squibb, Celgene, CTI BioPharma, Galena BioPharma, Genentech, Geron, Gilead Sciences, Incyte, Lilly Oncology, NS Pharma, Pfizer, Promedior, Roche, and Seattle Genetics.

Faculty

John Mascarenhas, MD

Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD, has disclosed that he has received consulting fees from Incyte and Novartis and funds for research support from CTI Biopharma, Incyte, Janssen, Merck, Novartis, Promedior, and Roche.

Raajit K. Rampal, MD, PhD

Assistant Member
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Incyte and funds for research support from Constellation.
Brady L. Stein, MD, MHS

Assistant Professor of Medicine
Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has disclosed that he has received consulting fees from Incyte.

Staff

Rachael M. Andrie, PhD

Associate Managing Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Ryan P. Topping, PhD

Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with polycythemia vera and myelofibrosis.

Goal

The goal of this activity is to improve participants’ competence in and performance at treating patients with polycythemia vera and myelofibrosis.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2018, through January 30, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

In this archived Webcast, Raajit K. Rampal, MD, PhD, provides expert perspectives on the diagnosis and optimal management of patients with polycythemia vera or myelofibrosis.

person default Raajit K. Rampal, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 30, 2018 Expiration: April 29, 2019

Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?

Julie M. Vose, MD, MBA Released: April 30, 2018

Shaji Kumar, MD, provides an overview of the latest research on smoldering multiple myeloma, with treatment strategies to consider for your patients.

Shaji Kumar, MD Released: April 18, 2018

In this CME-certified activity, Farhad Ravandi, MD, explores optimal current treatment of this rare leukemia, including standard systemic therapies and targeted approaches, as well as emerging therapies.

Farhad Ravandi, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: April 18, 2018 Expiration: April 17, 2019
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Incyte

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?